Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Roymans, Dirk ^a   Alnajjar, Sarhad S ^b   Battles, Michael B ^c   Sitthicharoenchai, Panchan ^b   Furmanova Hollenstein, Polina ^a   Rigaux, Peter ^a   Van Den Berg, Joke ^a   Kwanten, Leen ^a   Van Ginderen, Marcia ^a   Verheyen, Nick ^a   Vranckx, Luc ^a   Jaensch, Steffen ^d   Arnoult, Eric ^e   Voorzaat, Richard ^a   Gallup, Jack M ^b   Larios Mora, Alejandro ^b   Crabbe, Marjolein ^d   Huntjens, Dymphy ^d   Raboisson, Pierre ^a   Langedijk, Johannes P ^a   Ackermann, Mark R ^b   McLellan, Jason S ^c   Vendeville, Sandrine ^a   Koul, Anil ^a   more..

^a Janssen Research and Development   (Netherlands)

^b IOWA STATE UNIVERSITY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e Janssen R and D LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; HYBRID PROTEIN; JNJ 49153390; JNJ 49214698; JNJ 53718678; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS FUSION INHIBITOR; VIRUS RNA; IMIDAZOLIDINE DERIVATIVE; INDOLE DERIVATIVE; JNJ-53718678; VIRUS FUSION PROTEIN;

INFECTIVITY; INHIBITOR; OPTIMIZATION; PROTEIN; RESPIRATORY DISEASE; VIRUS; YOUNG POPULATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BEAGLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IN VIVO STUDY; LAMB; LOWER RESPIRATORY TRACT INFECTION; LUNG; MALE; METABOLIC STABILITY; MOUSE; NEWBORN; NONHUMAN; PROPHYLAXIS; PROTEIN STABILITY; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; CHEMICAL STRUCTURE; CHLOROCEBUS AETHIOPS; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; METABOLISM; PNEUMOVIRUS; RESPIRATORY MUCOSA; SHEEP; TUMOR CELL LINE; VERO CELL LINE; VIRUS PNEUMONIA;

ANIMALIA; OVIS ARIES; RESPIRATORY SYNCYTIAL VIRUS;

ANIMALS; ANIMALS, NEWBORN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; EPITHELIAL CELLS; HUMANS; IMIDAZOLIDINES; INDOLES; MOLECULAR STRUCTURE; PNEUMONIA, VIRAL; RATS; RESPIRATORY MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; SHEEP; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS; VIRAL FUSION PROTEIN INHIBITORS; VIRAL FUSION PROTEINS;

EID: 85026512944     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00170-x     Document Type: Article

References (77)

1. Hall, C. B. et al. The burden of respiratory syncytial virus in young children. N. Engl. J. Med. 360, 588-598 (2009).
2. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375, 1545-1555 (2010).
3. Rudan, I. et al. Epidemiology and etiology of childhood pneumonia. Bull. World Health Organ. 86, 408-416 (2008).
4. Falsey, A. R. et al. Respiratory syncytial virus infection in the elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759 (2005).
5. Simoes, E. A. F. Respiratory syncytial virus infection. Lancet 354, 847-852 (1999).
6. Lee, N. et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin. Infect. Dis. 57, 1069-1077 (2013).
7. Ruuskanen, O., Lahti, E., Jennings, L. C. & Murdoch, D. R. Viral pneumonia. Lancet 377, 1264-1275 (2011).
8. Stockman, L. J., Curns, A. T., Anderson, L. J. & Fischer-Langley, G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr. Infect. Dis. J. 31, 5-9 (2012).
9. Kim, Y. J. et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J. Infect. Dis. 209, 1195-1204 (2014).
10. Paramore, L. C., Ciuryla, V., Ciesla, G. & Liu, L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22, 275-284 (2004).
11. Anderson, L. J. et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31(Suppl 2), B209-B215 (2013).
12. Roymans, D. & Koul, A. Respiratory syncytial virus: a prioritized or neglected target ? Future Med. Chem. 2, 1523-1527 (2010).
13. Roymans, D. & Koul, A. in Human Respiratory Syncytial Virus Infection (ed. Resch, B.) 197-234 (InTech, 2011).
14. Wainwright, C. Acute viral bronchiolitis in children - a very common condition with few therapeutic options. Paediatr. Respir. Rev. 11, 39-45 (2010).
15. Mazur, N. I. et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir. Med. 3, 888-900 (2015).
16. Friedman, J. N. et al. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Paediatr. Child Health 19, 485-498 (2014).
17. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 118, 1774-1793 (2006).
18. Jardetzky, T. S. & Lamb, R. A. Activation of paramyxovirus membrane fusion and virus entry. Curr. Opin. Virol 5, 24-33 (2014).
19. McLellan, J. S., Ray, W. C. & Peeples, M. E. Structure and function of RSV surface glycoproteins. Curr. Top. Microbiol. Immunol. 372, 83-104 (2013).
20. Andries, K. et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral. Res. 60, 209-219 (2003).
21. Douglas, J. L. et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Virol. 77, 5054-5064 (2003).
22. Cianci, C. et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents. Chemother. 48, 413-422 (2004).
23. Bonfanti, J. F. et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 51, 875-896 (2008).
24. Bonfanti, J.-F. & Roymans, D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr. Opin. Drug Dev. 12, 479-487 (2009).
25. Mackman, R. L. et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J. Med. Chem. 58, 1630-1643 (2015).
26. Huntjens, D. R. H. et al. Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase I, double blind, randomized, placebo-controlled first-in-human study in healthy adult subjects. 2017. Clin. Pharmacokinet. doi: 10.1007/s40262-017-0522-8.
27. A study of AK0529 in infants hospitalized with RSV. https://clinicaltrials.gov/ct2/show/NCT02460016.
28. Safety and pharmacokinetics study of multiple ascending doses of BTA-C585 in healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT02668367.
29. Cianci, C. et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Nat Acad. Sci. USA 101, 15046-15051 (2004).
30. Roymans, D. et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc. Natl Acad. Sci. USA 107, 308-313 (2010).
31. Douglas, J. L. et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus by similar mechanisms. Antimicrob. Agents Chemother. 49, 2460-2466 (2005).
32. McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
33. Yan, D. et al. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc. Natl Acad. Sci. USA 111, E3441-E3449 (2014).
34. Battles, M. B. et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat. Chem. Biol. 12, 87-93 (2016).
35. McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013).
36. Yunus, A. S. et al. Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation. Virology 396, 226-237 (2010).
37. Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun 6, 8143 (2015).
38. Villenave, R., Shields, M. D. & Power, U. F. Respiratory syncytial virus interaction with human airway epithelium. Trends Microbiol. 21, 238-244 (2013).
39. Ackermann, M. R. Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. ILAR J. 55, 4-15 (2014).
40. Derscheid, R. J. & Ackermann, M. R. Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses 4, 2359-2378 (2012).
41. Derscheid, R. J. & Ackermann, M. R. The innate immune system of the perinatal lung and responses to respiratory syncytial virus infection. Vet. Pathol. 50, 827-841 (2013).
42. Bem, R. A., Domachowske, J. B. & Rosenberg, H. F. Animal models of human respiratory syncytial virus disease. Am. J. Physiol. Lung. Cell Mol. Physiol. 301, L148-L156 (2011).
43. Welliver, T. P. et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195, 1126-1136 (2007).
44. Van Woensel, J. B., Kimpen, J. L. & Brand, P. L. Respiratory tract infections caused by respiratory syncytial virus in children. Diagnosis and treatment. Minerva Pediatr 53, 99-106 (2001).
45. American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97, 137-140 (1996).
46. Russell, C. D. et al. The human immune response to respiratory syncytial virus infection. Clin. Microbiol. Rev. 30, 481-502 (2017).
47. Rossi, G. A. & Colin, A. A. Respiratory syncytial virus-host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life. Pediatr. Allergy Immunol. 28, 320-331 (2017).
48. DeVincenzo, J. P. et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 182, 1305-1314 (2010).
49. DeVincenzo, J. P. et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N. Engl. J. Med. 371, 711-722 (2014).
50. DeVincenzo, J. P. et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N. Engl. J. Med. 373, 2048-2058 (2015).
51. El Saleeby, C. M. et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J. Infect. Dis. 204, 996-1002 (2011).
52. Buckingham, S. C., Bush, A. J. & DeVincenzo, J. P. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants. Pediatr. Infect. Dis. J. 19, 113-117 (2000).
53. DeVincenzo, J. P., El Saleeby, C. M. & Bush, A. J. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis. 191, 1861-1868 (2005).
54. DeVincenzo, J. P. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr. Res. 56, 914-917 (2004).
55. Larios Mora, A. et al. Kinetics of respiratory syncytial virus (RSV) memphis strain 37 (M37) infection in the respiratory tract of newborn lambs as an RSV infection model for human infants. PLoS ONE 10, e0143580 (2015).
56. DeVincenzo, J. P., Aitken, J. B. & Harrison, L. G. Opportunities for early therapy of respiratory syncytial virus (RSV) infection: what happens before hospitalization. Antiviral. Res. 62, 47-51 (2004).
57. Samuel, D. et al. GS-5806 inhibits pre- to post-fusion conformational changes of the RSV fusion protein. Antimicrob. Agents. Chemother. 59, 7109-7112 (2015).
58. Cooymans, L. P. et al. Benzimidazole respiratory syncytial virus inhibitors. WO2012080446 (2012).
59. Cooymans, L. P. et al. Indoles as respiratory syncytial virus antiviral agents. WO2012080447 (2012)
60. Lohmann, V. et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77, 3007-3019 (2003).
61. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999).
62. Sun, D. & Nassal, M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J. Hepatol. 45, 636-645 (2006).
63. Hallak, L. K., Spillmann, D., Collins, P. L. & Peeples, M. E. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 74, 10508-10513 (2000).
64. Roth, J. P. et al. A recombinant infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays. Antiviral. Res. 82, 12-21 (2009).
65. Shirogane, Y. et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J. Virol. 82, 8942-8946 (2008).
66. Hashimoto, K. et al. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J. Virol. 76, 6743-6749 (2002).
67. Schoggins, J. W. et al. Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc. Natl Acad. Sci. USA 109, 14610-14615 (2012).
68. Marschall, M. et al. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrobial. Agents Chemother 44, 1588-1597 (2000).
69. Kwanten, L., De Clerck, B. & Roymans, D. in Antiviral Methods and Protocols 2nd edn (ed. Gong, E. Y.) 337-344 (Humana Press, 2013).
70. Van den Berg, J., Kwanten, L. & Roymans, D. in Antiviral Methods and Protocols 2nd edn (ed. Gong, E. Y.) 365-372 (Humana Press, 2013).
71. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011).
72. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution ? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
73. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
74. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
75. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
76. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
77. Cornelissen, F., Cik, M. & Gustin, E. Phaedra, a protocol-driven system for analysis and validation of high-content imaging and flow cytometry. J. Biomol. Screen 17, 496-506 (2012).